Best of ASCO - 2014 Annual Meeting

 

Welcome

Other

Melanoma/Skin Cancers

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
Cancer Immune Control Dynamics (CICD): A clinical data driven model of systemic immunity.

Svetomir Markovic

e21058

Challenges in sentinel node (SN) pathology in the era of adjuvant treatment: The risk of over and undertreatment stress the need for expert pathology review.

Viola Franke

9593

Characterization of mechano-microenvironment of acral melanoma and its potential impact on tumor cell invasion.

Xin Yi

e21062

Extra-mammary Paget’s disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.

Julie Tse

9591

Genetic relationship between pilar cysts, pilar tumors and pilar carcinomas.

Rachael Hagen

e21063

Mucosal melanoma of the female genital tract: Operation modalities.

Xuan Wang

e21060

Nation-wide trends in mortality of patients with ocular and orbit melanoma: 2000 to 2014.

William Forehand

e21061

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

Irene Reijers

TPS9605

Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors.

Kyriakos P. Papadopoulos

9509

Postoperative radiotherapy in resected sinonasal mucosal melanoma.

Li Zhou

e21059

Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).

Jessica Yang

9592

Somatic mutational profile of Merkel cell carcinoma treated with immune checkpoint blockade: Preliminary results from a planned multiplatform analysis.

Evan Rosenbaum

e21064

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

Ahmad A. Tarhini

9504